Cempra Pharmaceuticals announced that enrollment is underway in its Phase 2/3 trial with CEM-102 for patients suffering from acute bacterial skin structure infections (ABSSI). This adaptive design, randomized, double-blind, multi-center study will evaluate the safety and efficacy of orally-administered CEM-102 compared to linezolid in the treatment of ABSSIs in an estimated 880 patients requiring 10 to 14 days of antibacterial therapy.  

CEM-102 is an oral antibiotic being developed in the United States for the treatment of staphylococcal infections including hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) and community-acquired MRSA (CA-MRSA).

For more information call (919) 467-1716 or visit www.cempra.com.